Bristol Myers Squibb and Others Offer Up to 6.6% Dividend Yields
Written by Emily J. Thompson, Senior Investment Analyst
Source: Fool
- Bristol Myers Squibb's Dividend Appeal: Bristol Myers Squibb offers a 4.5% dividend yield, and despite facing patent cliff risks, its 85% payout ratio indicates a safety margin, with expectations to continue developing new drugs to maintain revenue stability.
- Stability of Realty Income: Realty Income boasts a 5.3% dividend yield and a 30-year streak of annual dividend increases, demonstrating reliability in an inflationary environment, making it suitable for conservative income-seeking investors.
- Enterprise Products Partners' Cash Flow: Enterprise Products Partners has a distribution yield of 6.6%, with distributable cash flow covering its distribution 1.7 times, indicating robustness in the energy infrastructure sector, making it a solid long-term hold.
- Diverse Investment Opportunities: Bristol Myers Squibb, Realty Income, and Enterprise Products Partners come from different sectors, offering attractive dividend yields, suggesting that investors should look beyond tech stocks to find these high-yield opportunities for better investment returns.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMY is 55.86 USD with a low forecast of 37.00 USD and a high forecast of 68.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 54.220
Low
37.00
Averages
55.86
High
68.00
Current: 54.220
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
